Clinical proteomics and mass spectrometry profiling for cancer detection

被引:38
作者
Solassol, Jerome
Jacot, William
Lhermitte, Ludovic
Boulle, Nathalie
Maudelonde, Thierry
Mange, Alain
机构
[1] Hop Arnaud de Villeneuve, Biol Cellulaire Lab, INSERM, U540, F-34295 Montpellier 5, France
[2] Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France
关键词
biomarker; cancer; clinical proteomics; Clinprot (TM); SELDI-TOF;
D O I
10.1586/14789450.3.3.311
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A key challenge in the clinical proteomics of cancer is the identification of biomarkers that would enable early detection, diagnosis and monitoring of disease progression to improve long-term survival of patients. Recent advances in proteomic instrumentation and computational methodologies offer a unique chance to rapidly identify these new candidate markers or pattern of markers. The combination of retentate affinity chromatography and mass spectrometry is one of the most interesting new approaches for cancer diagnostics using proteomic profiling. This review presents two technologies in this field, surface-enhanced laser desorption/ionization time-of-flight and Clinprot(TM), and aims to summarize the results of studies obtained with the first of them for the early diagnosis of human cancer. Despite promising results, the use of the proteomic profiling as a diagnostic tool brought some controversies and technical problems, and still requires some efforts to be standardized and validated.
引用
收藏
页码:311 / 320
页数:10
相关论文
共 87 条
[41]  
Mehta AI, 2003, DIS MARKERS, V19, P1
[42]  
Melle C, 2006, INT J ONCOL, V28, P195
[43]   Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach [J].
Melle, C ;
Ernst, G ;
Schimmel, B ;
Bleul, A ;
Kaufmann, R ;
Hommann, M ;
Richter, KK ;
Daffner, W ;
Settmacher, U ;
Claussen, U ;
von Eggeling, F .
JOURNAL OF PROTEOME RESEARCH, 2005, 4 (05) :1799-1804
[44]  
Melle C, 2004, INT J ONCOL, V24, P885
[45]   Biomarker discovery and identification in laser microdissected head and neck squamous cell carcinoma with ProteinChip® technology, two-dimensional gel electrophoresis, tandem mass spectrometry, and immunohistochemistry [J].
Melle, C ;
Ernst, G ;
Schimmel, B ;
Bleul, A ;
Koscielny, S ;
Wiesner, A ;
Bogumi, R ;
Möller, U ;
Osterloh, D ;
Halbhuber, KJ ;
von Eggeling, F .
MOLECULAR & CELLULAR PROTEOMICS, 2003, 2 (07) :443-452
[46]  
Merrell Karen, 2004, J Biomol Tech, V15, P238
[47]   Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology [J].
Mok, SC ;
Chao, J ;
Skates, S ;
Wong, KK ;
Yiu, GK ;
Muto, MG ;
Berkowitz, RS ;
Cramer, DW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (19) :1458-1464
[48]   Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1 [J].
Moshkovskii, SA ;
Serebryakova, MV ;
Kuteykin-Teplyakov, KB ;
Tikhonova, OV ;
Goufman, EI ;
Zgoda, VG ;
Taranets, IN ;
Makarov, OV ;
Archakov, AI .
PROTEOMICS, 2005, 5 (14) :3790-3797
[49]   Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry [J].
Neuhoff, NV ;
Kaiser, T ;
Wittke, S ;
Krebs, R ;
Pitt, A ;
Burchard, A ;
Sundmacher, A ;
Schlegelberger, B ;
Kolch, W ;
Mischak, H .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2004, 18 (02) :149-156
[50]   Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases [J].
Paradis, V ;
Degos, F ;
Dargère, D ;
Pham, N ;
Belghiti, J ;
Degott, C ;
Janeau, JL ;
Bezeaud, A ;
Delforge, D ;
Cubizolles, M ;
Laurendeau, I ;
Bedossa, P .
HEPATOLOGY, 2005, 41 (01) :40-47